13F Holdings
中文EN

QUIT ACHIEVE LIFE SCIENCES, INC.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 949858 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.4%
TTM EPS YoY-4.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-104.2%
ROA-86.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio10.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-52.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense—$22.82M$15.81M$30.08M$23.97M
SG&A expense—$16.25M$11.44M$10.72M$9.13M
Interest expense$819,000$2.18M$2.85M$1.79M—
Pretax income-$54.65M-$39.83M-$29.82M-$42.35M-$33.15M
Net income-$54.65M-$39.83M-$29.82M-$42.35M-$33.15M
EPS (basic)-1.25-1.24-1.50-4.00-4.08
EPS (diluted)-1.25-1.24-1.50-4.00-4.08
Weighted avg. shares (diluted)43.59M32.07M19.83M10.59M8.12M
Balance sheet
Cash & equivalents$20.93M$12.75M$15.55M$24.77M$43.02M
Short-term investments$15.47M$21.61M———
Current assets$39.89M$36.47M$16.98M$27.33M$44.59M
PP&E, net$3,000$8,000$13,000$4,000$15,000
Goodwill$1.03M$1.03M$1.03M$1.03M$1.03M
Intangibles$751,000$974,000$1.20M$1.42M$1.64M
Total assets$41.79M$38.63M$19.37M$29.97M$47.52M
Current liabilities$9.08M$6.68M$20.81M$21.60M$4.55M
Total liabilities$20.27M$17.73M$20.82M$21.67M$19.47M
Shareholders' equity$21.52M$20.90M-$1.45M$8.30M$28.04M
Shares outstanding53.23M34.69M21.17M17.90M9.45M
Cash flow statement
Operating cash flow-$49.47M-$29.77M-$24.48M-$37.57M-$29.44M
Capital expenditure$3,000—$21,000——
Free cash flow-$49.47M—-$24.50M——
Investing cash flow$6.11M-$21.58M-$21,000——
Financing cash flow$51.53M$48.53M$15.28M$19.32M$36.61M
Depreciation & amortization$228,000$229,000$228,000$236,000$250,000
Stock-based compensation$8.76M$5.33M$3.44M$3.27M$2.19M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.